2HG accumulation results from isocitrate dehydrogenase (IDH) genetic mutation in LGGs and this, combined with the integration of IDH mutation status in the WHO 2016 gliomas’ reclassification, suggests that the metabolite could be used as a state-of-the-art biomarker for IDH-mutant gliomas.40 Additionally, it has been established through several clinical trials that 2HG can be identified by MRS.41,42 Two studies have conveyed the significance of integrating 2HG-MRS into monitoring IDH-mutant gliomas. This evidence concerns the gene IDH3A and central nervous system cancer.